Chukwunonso Nwabufo, MBA, PhD
Pharmacologist, Entrepreneur, Transformational leader
I am a Pharmacologist
I am an Entrepreneur
I am a Transformational Leader
What I do
I deploy pharmacological principles to develop safe and effective drugs for unmet medical needs
I am advancing the implementation of precision medicine in global healthcare through OneDrug’s innovative medical devices
I use my creative and innovative skills to solve the world’s most pressing problems in global healthcare
My Services
Unlimited Elements Error: Error in widget Icon Bullets, You have some other plugin that loaded another version of twig. It's uncompatable with unlimited elements unfortunatelly.
Unlimited Elements Error: Error in widget Content Box Hover Text Reveal, You have some other plugin that loaded another version of twig. It's uncompatable with unlimited elements unfortunatelly.
Unlimited Elements Error: Error in widget Content Box Hover Text Reveal, You have some other plugin that loaded another version of twig. It's uncompatable with unlimited elements unfortunatelly.
Unlimited Elements Error: Error in widget Content Box Hover Text Reveal, You have some other plugin that loaded another version of twig. It's uncompatable with unlimited elements unfortunatelly.
Portfolio
Research and Development
Entrepreneurship
Transformational Leadership
Impact Highlight
Dr. Chukwunonso Nwabufo
Live. Powerful. Impactful
Dr. Chukwunonso Nwabufo is a Postdoctoral Scholar in the Department of Bioengineering, School of Medicine and College of Engineering, University of Washington, where he is developing novel microdevices for precision medicine applications. Dr. Nwabufo is the founder and CEO of OneDrug Inc., an innovative medical technology startup that is developing smart point-of-care technologies to advance the clinical implementation of precision medicine across the globe. He is a multiple award-winning translational pharmacologist with over eight years of experience in drug development across academia and the pharmaceutical industry. Dr. Nwabufo contributed to the development of Remdesivir and Lenacapavir, approved for the treatment of COVID-19 and HIV, respectively, during his tenure at Gilead Sciences. He also contributed to the development of novel compounds under basic science research for the treatment and/or diagnosis of Parkinson’s disease during his MSc program.
Dr. Nwabufo’s doctoral research work was focused on deploying pharmacological strategies to improve the clinical efficacy and safety profile of promising COVID-19 drugs. He has received numerous prestigious awards, including the Canadian Institutes of Health Research Canada Graduate Scholarship Doctoral Award, Canadian Institutes of Health Research Canada Graduate Scholarship – Michael Smith Foreign Study Supplements Award, Emerging Academic Scholars Award, Pfizer Canada Fellowship, Top 25 Canadian Immigrant for Healthcare Innovation, and 2024 Canadian CEO of the Year Award for Medical Technology Development. In general, he has received more than 35 international and national awards and recognitions with over $400,000 in funding due to academic, research, and leadership accomplishments. Dr. Nwabufo has authored 19 peer-reviewed scientific papers and 11 industry-standard peer-reviewed reports in support of drug development programs.
Dr. Nwabufo serves as an editorial board member of Drug Metabolism Reviews and Journal of Applied Bioanalysis. He has served as a Track Leader and Abstract Screener for the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 Conference, and as Past Chair, Chair, and Vice Chair of the AAPS Pharmacokinetics, Pharmacodynamics, and Drug Metabolism Community. In addition, he contributes to the advancement of clinical pharmacology education and mentorship as a member of the Student, Trainee, and Early-Stage Professional Committee of the American College of Clinical Pharmacology.
Unlimited Elements Error: Error in widget Scroll Image Reveal, You have some other plugin that loaded another version of twig. It's uncompatable with unlimited elements unfortunatelly.
Milestones
University of Toronto, Canada
- PhD Pharmaceutical Sciences, 4.0/4.0 ‖ 2025
Quantic School of Business and Technology, USA
- Master of Business Administration, 93% ‖ 2021
University of Saskatchewan, Canada
- MSc Pharmacy, 90.5% ‖ 2019
University of Benin, Nigeria
- BSc Biochemistry, 91% ‖ 2015
Postdoctoral Scholar
- Bioengineering, School of Medicine, University of Washington ‖ 2025–Present
OneDrug
- Founder and CEO ‖ 2021–Present
Gilead Sciences, Canada
- Senior Research Associate, Analytical Operations ‖ 2019–2021
Approved Life-saving Drugs
- 2 approved and commercialized life-saving medicines
COVID-19 Drug Development
- 7 high-impact scientific papers supporting the development of transformative medicines for COVID-19
Drug Development for Parkinson’s Disease
- 3 novel compounds under basic science research for the treatment and/or diagnosis of Parkinson’s disease.
- 4 high-impact scientific papers supporting drug development for Parkinson’s disease.
- 1 most-read paper, 2 trending papers, and 1 paper with over 12k readership.
Pharmacology and Therapeutics
- Served as Guest Editor for a special issue of Drug Metabolism Reviews focused on improving predictive power of preclinical models for expedited drug development, featuring nine contributions from leading experts.
- The 9 published articles achieved strong metrics: 16,512+ total reads, 22 total altmetric score, and 144+ citations.
Drug Metabolism Reviews
- Editorial Board Member
American Association of Pharmaceutical Scientists, USA
- Chair, Pharmacokinetic, Pharmacodynamic, & Drug Metabolism Community
Journal of Applied Bioanalysis
- Editorial Board Member
Science Rendezvous
- Judge, SRHacks Hackathon
Western Canadian Medicinal Chemistry Workshop
- 2018 Session Co-chair
COVID-19 Drug Development
- Chukwunonso K. Nwabufo§ (2025) Severe acute respiratory syndrome coronavirus 2–mediated dysregulation of drug processing genes is dependent on pathogenic variants, target site of infection, age, and sex. Drug Metab Dispos. https://doi.org/10.1016/j.dmd.2025.100152
- Chukwunonso K. Nwabufo§ (2025) COVID-19 Alters Inflammatory, Mitochondrial, and Protein Clearance Pathway Genes: Potential Implications for New-onset Parkinsonism in Patients. J Neuroimmune Pharmacol. 20, 58. https://doi.org/10.1007/s11481-025-10215-4
- Chukwunonso K. Nwabufo§ (2025) Uncovering the Impact of COVID-19 Mediated Bidirectional Dysregulation of CYP3A4 on Systemic and Pulmonary Drug Concentrations Using Physiologically Based Pharmacokinetic Modeling. Drug Metab Dispos. https://doi.org/10.1124/dmd.124.001893
- Chukwunonso K. Nwabufo§ et al. (2024) COVID-19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.16124
- Chukwunonso K. Nwabufo§ et al. (2023) SARS-CoV-2 Infection Dysregulates Clinically Relevant Drug Metabolizing Enzymes and Transporters. Front. Pharmacol. link
- Chukwunonso K. Nwabufo & Reina Bendayan (2022) Pharmacokinetic Considerations to Optimize Clinical Outcomes for COVID-19 Drugs. Trends Pharmacol. Sci. https://doi.org/10.1016/j.tips.2022.09.005
- Chukwunonso K. Nwabufo & Omozojie P. Aigbogun (2022) Potential Application of Mass Spectrometry Imaging in Pharmacokinetic Studies. Xenobiotica. https://doi.org/10.1080/00498254.2022.2119900
Drug Development for Parkinson’s Disease
- Omozojie P. Aigbogun, Chukwunonso K. Nwabufo et al. (2022) An HPLC-UV validated bioanalytical method for α-synuclein binding compounds. Xenobiotica. https://doi.org/10.1080/00498254.2022.2140315
- Chukwunonso K. Nwabufo & Omozojie P. Aigbogun (2022) Diagnostic and Therapeutic Agents Targeting Alpha-synuclein. J Neurol. https://doi.org/10.1007/s00415-022-11267-9
- Chukwunonso K. Nwabufo et al. (2021) PET Probe Design for α-synuclein Binding Compounds. Xenobiotica. https://doi.org/10.1080/00498254.2021.1943566
- Chukwunonso K. Nwabufo & Ed S. Krol (2019) Metabolic Fate of Novel Dimer Compounds for Parkinson’s Disease. Drug Metab Pharmacokinet. 10.1016/j.dmpk.2018.09.208
- Chukwunonso K. Nwabufo et al. (2019) Tandem MS Analysis of Novel Caffeine Scaffold Compounds. Rapid Commun Mass Spectrom. https://doi.org/10.1002/rcm.8540
Pharmacology and Therapeutics
- Gurveer Kaur & Chukwunonso K. Nwabufo* (2024) Pharmacogenetic-Guided Treatment Implementation. Pharmacogenet Genomics. link
- Chukwunonso K. Nwabufo§ (2023) Mirvetuximab Soravtansine in Ovarian Cancer Therapy. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-023-04575-y
- Chukwunonso K. Nwabufo (2022) Relevance of ABC Transporters in Drug Development. Curr. Drug Metab. 10.2174/1389200223666220621113524
- Aarzoo Thakur et al. (2021) Bioanalytical Strategies in Drug Discovery and Development. Drug Metab Rev. https://doi.org/10.1080/03602532.2021.1959606
- Chukwunonso K. Nwabufo (2021) Introduction to Next Generation Drug Discovery. Drug Metab Rev. https://doi.org/10.1080/03602532.2021.1909614
- Laura E. Russell et al. (2021) Pharmacogenomics in the Era of Next Generation Sequencing. Drug Metab Rev. https://doi.org/10.1080/03602532.2021.1909613
- Laura E. Russell et al. (2020) Advances in the Study of Drug Metabolism – Symposium Report. Drug Metab Rev. https://doi.org/10.1080/03602532.2020.1765793
Biochemistry and Molecular Biology
- Chukwunonso K. Nwabufo & Olusanya Olasehinde (2017) Biochemical Effect of Hibiscus sabdariffa on Male Reproductive Hormones. Adv. Appl. Sci. Res. 8(2), 38–41.
- Chukwunonso K. Nwabufo & Ugbogbo, C. (2016) Designing Life: The Future of Genetic Engineering. Microbiology World 3(6), 51–55.
- Chukwunonso K. Nwabufo (2014) Hybridoma Technology: A Tool in Immunotherapy. Microbiology World 8, 29–37.
Opinion Editorials
Milestones
University of Toronto, Canada
PhD Pharmaceutical Sciences, 4.0/4.0 ‖ 2024
Quantic School of Business and Technology, USA
Master of Business Administration, 93% ‖ 2021
University of Saskatchewan, Canada
MSc Pharmacy, 90.5% ‖ 2019
University of Benin, Nigeria
BSc Biochemistry, 91% ‖ 2015
OneDrug
Founder and CEO ‖ 2021-Present
Gilead Sciences, Canada
Senior Research Associate, Analytical Operations ‖ 2019-2021
Approved Life-saving Drugs
- https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/sunlenca-lenacapavir-receives-fda-approval-as-a-firstinclass-twiceyearly-treatment-option-for-people-living-with-multidrug-resistant-hiv
- https://www.gilead.com/news-and-press/press-room/press-releases/2020/10/us-food-and-drug-administration-approves-gileads-antiviral-veklury-remdesivir-for-treatment-of-covid19#:~:text=(Nasdaq%3A%20GILD)%20today%20announced,virus%20that%20causes%20COVID%2D19.
COVID-19 Drug Development
- https://doi.org/10.1016/j.tips.2022.09.005
- https://www.eventscribe.net/2022/PharmSci360/index.asp?posterTarget=528858
- https://www.tandfonline.com/doi/full/10.1080/00498254.2022.2119900
Drug Development for Parkinson’s disease
- https://www.tandfonline.com/doi/full/10.1080/00498254.2022.2140315
- https://www.tandfonline.com/doi/full/10.1080/00498254.2021.1943566
- https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/full/10.1002/rcm.8540
- https://link.springer.com/article/10.1007/s00415-022-11267-9
Pharmacology and Therapeutics
Drug Metabolism Reviews
Editorial Board Member
American Association of Pharmaceutical Scientists, USA
Vice Chair, Pharmacokinetic, Pharmacodynamic, & Drug Metabolism Community
Science Rendezvous
Judge, 2022 SRHacks Hackathon
Western Canadian Medicinal Chemistry Workshop
2018 Session Co-chair
Unlimited Elements Error: Error in widget Logo Carousel, You have some other plugin that loaded another version of twig. It's uncompatable with unlimited elements unfortunatelly.
Awards and Honors
Unlimited Elements Error: Error in widget Logo Grid, You have some other plugin that loaded another version of twig. It's uncompatable with unlimited elements unfortunatelly.
Media Appearance
Leading Scientific Associations
Renowned Academic Institutions
News Outlet
https://www.hilltimes.com/story/2021/06/02/dont-let-the-next-pandemic-meet-this-pharmaceutical-sector/269104/
- https://www.alzforum.org/papers/diagnostic-and-therapeutic-agents-target-alpha-synuclein-parkinsons-disease
- https://www.alzforum.org/papers/employing-vitro-metabolism-guide-design-f-labelled-pet-probes-novel-synuclein-binding
- https://www.alzforum.org/papers/hplc-uv-validated-bioanalytical-method-measurement-vitro-phase-1-kinetics-synuclein-binding
Latest Blog
Unlock the Thrills of CryptoCasino: A Crypto Gaming Experience like No Other
In the vast expanse of online casinos, CryptoCasino stands out as a beacon of innovation and excitement. This CryptoCasino Online Casino and Sportsbook is a
AllySpin: Απελευθερώνοντας Απερίσπαστο Δυναμικό Παιχνιδιού
Για όσους λαχταρούν τον ενθουσιασμό του spin, το AllySpin είναι ο απόλυτος προορισμός. Ως έμπειρος παίκτης, πιθανότατα δεν είστε ξένος με την αδρεναλίνη που ρέει
Ways to get money on a 50 free spins no deposit burlesque queen cruiseship
Content Local casino Cruise Withdrawals: 50 free spins no deposit burlesque queen Individual Countries vs Real Harbors: Which Tends to make a better Cruise Time?
Further information can be found on our website. The link below will take you to a page containing a wealth of interesting and useful information.